- Exchange: Copenhagen
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Specialty Pharmaceuticals
Snapshot for H Lundbeck A/S (LUN)
| Open: | 100.9000 | Day's Range: | 100.3000 - 102.7000 | Volume: | 225,300 |
|---|---|---|---|---|---|
| Previous Close: | 101.2000 | 52wk Range: | 78.0000 - 128.5000 | 1-Yr Rtn: | -15.93% |
Key Statistics for LUN
| Current P/E Ratio (ttm) | 12.8967 |
|---|---|
| Estimated P/E(12/2013) | 13.0059 |
| Relative P/E vs. KFX | 0.6253 |
| Earnings Per Share (DKK) (ttm) | 7.9245 |
| Est. EPS (DKK) (12/2013) | 7.8580 |
| Est. PEG Ratio | - |
| Market Cap (M DKK) | 20,046.15 |
| Shares Outstanding (M) | 196.15 |
| 30 Day Average Volume | 250,838 |
| Price/Book (mrq) | 1.4345 |
| Price/Sale (ttm) | 1.2847 |
| Dividend Indicated Gross Yield | 1.96% |
| Cash Dividend (DKK) | 2.0000 |
| Last Dividend | 03/22/2013 |
| 5 Year Dividend Growth | -4.82% |
| Next Earnings Announcement | 08/07/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for LUN
Company Profile & Key Executives for LUN
H. Lundbeck A/S is an international pharmaceutical company. The Company researches, manufactures, and sells drugs for the treatment of psychiatric and neurological disorders. The Company focuses on mood disorders, dementia, anxiety, and sleep disorders. Lundbeck does research both in-house and in cooperation with research centers. The Company markets its products worldwide.
| Thorleif KrarupDeputy Chairman | Christian DyvigVice Chairman |
| Ulf WiinbergPresident/CEO | Anders GotzscheExec VP/CFO |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
LUN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page